Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Bipolar Depression: The Dating Game

neuroscienceCME Webcast

Premiere Date: Monday, November 21, 2016

This activity offers CE credit for:

1. Physicians (CME)
2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, November 21, 2017
Note: Credit Is No Longer Available

Faculty

Charles B. Nemeroff, MD, PhD  Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX

Joseph R. Calabrese, MD  Bipolar Disorders Research Chair and Professor of Psychiatry Case Western Reserve University School of Medicine Director, Mood Disorders Program University Hospitals Case Medical Center Cleveland, OH

Mark A. Frye, MD  Professor and Chair, Department of Psychiatry and Psychology Stephen & Shelly Jackson Family Professorship in Individualized Medicine Director, Mayo Clinic Depression Center Mayo Clinic Rochester, MN

Ned H. Kalin, MD  Hedberg Professor and Chair Department of Psychiatry University of Wisconsin School of Medicine and Public Health--Madison Director, HealthEmotions Research Institute Madison, WI Editor-in-Chief – American Journal of Psychiatry

Statement of Need

This video is a replay of a plenary session from the 9th Annual Chair Summit Master Class for Neuroscience Professional Development held in Miami, Florida on September 15 – 17, 2016.

Learning Objectives

At the end of this CE activity, participants should be able to:

Describe the recent changes in DSM-V that define the mixed feature specifier for a diagnosis of depression.

Financial Support

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

Target Audience

Physicians, physician assistants, nurse practitioners, and other healthcare professionals with an interest in psychiatry, neurology, and the neurosciences.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/20186 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Nemeroff has disclosed that he receives grants/research support from National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Fortress Biotech; Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); Xhale, Inc. He is a stockholder of AbbVie Inc.; Bracket; Celgene Corporation; Intermediate Holding Corp.; Network Life Sciences Inc.; OPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; Xhale, Inc. He has patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He serves on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara); Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Laureate Institute for Brain Research, Inc. RiverMend Health, LLC; Skyland Trail; Xhale, Inc. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc. He receives income sources or equity of $10,000 or more from American Psychiatric Publishing; Bracket (Clintara); Takeda Pharmaceuticals North America, Inc.; Xhale, Inc.

Dr. Calabrese has no disclosures to report.

Dr. Frye has disclosed that he receives grant support from AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for Medical Education and Research; Myriad Genetics; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Mental Health (NIMH); Pfizer Inc. He serves as a consultant to Janssen Research & Development, LLC; Mitsubishi Tanabe Pharma Corporation; Myriad Genetics; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals USA. He receives CME/Travel Support by American Physician Institute. His disclosure declaration: Mayo Clinic 2015 ? Mayo Clinic has a financial interest in AssureRX and the technology referenced in this publication/presentation.

Dr. Kalin has disclosed that he receives grant support from the National Institutes of Health (NIH), Principal Investigator and the National Institute of Mental Health (NIMH, Principal Investigator. He is a stock shareholder of Correct Therapeutics. He receives honoraria from Pritzker Neuropsychiatric Disorders Research Consortium. He serves as a consultant for Elsevier, Co-Editor.

Howard Bliwise, MD (peer reviewer) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).